# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Reni Benjamin maintains CTI BioPharma (NASDAQ:CTIC) with a Market Perform.
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
SVB Leerink analyst Andrew Berens downgrades CTI BioPharma (NASDAQ:CTIC) from Outperform to Market Perform and lowers the pr...
Stifel analyst Benjamin Burnett downgrades CTI BioPharma (NASDAQ:CTIC) from Buy to Hold and raises the price target from $8....
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. •...
JMP Securities analyst Reni Benjamin downgrades CTI BioPharma (NASDAQ:CTIC) from Market Outperform to Market Perform.